

Pain Therapeutics

Drugs, Markets & Companies

By

Prof. K. K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland

November 2021

A Jain PharmaBiotech Report

A U T H O R ' S B I O G R A P H Y

Professor K. K. Jain is a neurologist/neurosurgeon with specialist qualifications including Fellowships of the Royal Colleges of Surgeons in Australia and Canada. He has trained, practiced and held academic positions in several countries including Switzerland, India, Iran, Germany Canada and USA. After retirement from neurosurgery, Prof. Jain remains a consultant in neurology. He is also working in the biotechnology/biopharmaceuticals industry and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently is the CEO at Jain PharmaBiotech.

Prof. Jain's 492 publications include 35 books (6 as editor+ 29 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals, biomarkers: proteomics, molecular diagnostics, nanobiotechnology, and personalized medicine. Contributions to MedLink, an accredited continuing education program for neurologists, include 172 articles out of a total of 1250 articles by 450 authors. These articles are updated on a yearly basis. Prof. Jain's earlier books were the first in the areas covered: "Handbook of Laser Neurosurgery" (Charles C. Thomas, Springfield, Ill, 1983) and "Textbook of Hyperbaric Medicine" (1st ed in 1990 and 6th ed by Springer, 2017). His "Textbook of Gene Therapy" was translated into Chinese in 2000. Recent books include "Handbook of Nanomedicine" (Springer 2008, Chinese edition by Peking University Press 2011, 3rd ed 2017), "Textbook of Personalized Medicine" (Springer 2009; Japanese ed 2012; 2nd ed Springer 2015, 3rd ed 2021), "Handbook of Biomarkers" (Springer 2010; Chinese ed, Chemical Industry Press 2016, 2nd ed 2017), "Drug-induced Neurological Disorders", 4th ed (Springer 2021), "Handbook of Neuroprotection" (Springer 2011, 2nd ed 2019), "Applications of Biotechnology in Cardiovascular Therapeutics" (Springer 2011), "Applications of Biotechnology in Neurology" (Springer 2013), and "Applications of Biotechnology in Oncology" (Springer 2014). He has also edited 3 editions of "Drug Delivery System" (Springer 2008, 20012 and 2020) and "Applied Neurogenomics" (Springer 2015). Lectures on personalized medicine given at Kazakh National Medical University, Kazakhstan were translated into Russian and published as a book "Essentials of Personalized Medicine" (LITERRA Publishing House, Moscow, 2019). Currently, he is writing "The Handbook of Alzheimer Disease" to be published by Springer in 2022.

A B O U T T H I S R E P O R T

The pain report is an update with inclusion of commercial information in an earlier publication titled "Pain Therapeutics: A strategic re-evaluation" published by Reuter's Business Insight/Datamonitor UK in 2000. Other reports written by Prof. Jain in the past have been published by PJB Publications, D & MD, Informa, and Decision Resources Inc. This is one of the in-house publications of Jain PharmaBiotech that are constantly updated.

November 2021
Copyright ©2021 by

Jain PharmaBiotech
Bläsiring 7
CH-4057 Basel
Switzerland

Tel & Fax: +4161-6924461
Email: info@pharmabiotech.ch
Web site: http://pharmabiotech.ch/

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

T A B L E O F C O N T E N T S

0. Executive Summary	18
1. Basic Aspects of Pain	20
Introduction	20
Historical aspects of pain.....	20
Pain definitions.....	22
A glossary of terms relevant to pain	23
Pain classification and description.....	23
Neuropathic pain.....	24
Refractory neuropathic pain	25
Classification of neuropathic pain according to levels	25
Cancer pain.....	26
Bone pain in cancer.....	28
Complex regional pain syndrome	28
Mechanisms of pain	29
Pain pathways	29
Pain organ of the skin.....	31
Role of nociceptors in pain transmission.....	32
Gate control and neuromatrix theories of pain	32
Pain mediators	33
Modulation of pain by pictures associated with social contacts	34
Modulation of pain by emotions	34
Role of the sympathetic nervous system in pain.....	34
Pathomechanism of inflammatory pain	34
Pathomechanism of visceral pain	35
Pathomechanism of neuropathic pain	36
Role of intact nerve fibers in neuropathic pain	36
Chemokines as mediators of neuropathic pain	36
Cancer therapy-induced neuropathic pain	36
CNS innate immunity and neuropathic pain	37
Cytokines as mediators of neuropathic pain.....	37
Free radicals in generation of neuropathic pain	37
GABA deficiency in neuropathic pain.....	38
Genetic basis of neuropathic pain.....	38
Gene expression changes in neuropathic pain.....	38
Glial activation and neuropathic pain	39
Immune cell-derived opioids and neuropathic pain	39
Spinal leptin and neuropathic pain	39
Tetrahydrobiopterin regulates neuropathic pain sensitivity	40
Pathomechanism of migraine.....	40
Role of the immune system in pain	41
Pain and itch	41
Pathomechanism of itch.....	41
Clinical aspects of itch	42
Molecular pathophysiology of pain.....	43
Role of ion channels in pain.....	43
Acid-sensing ion channels	43
Calcium channels in pain.....	44
P2X3 ion channels.....	44
Potassium ion channels.....	44
Sodium ion channels in pain	45
TRP ion channels in pain	46
Genetic basis of pain	47
Alternative RNA splicing and pain	48
Study of genes in pain	48
Pain as a channelopathy	49
Pain in the brain	49
Effect of chronic pain on opioid receptors in the brain	50
Neuropathic pain-induced morphological changes in the brain	50
Pain and dementia	50
Change from acute to chronic pain	50
Acute versus chronic pain	51
Descending facilitatory modulation of pain	51
Development of chronic pain following severe accidental injury.....	51
Pain and transcriptional repressor DREAM	52
Role of neuronal plasticity in pain.....	52
Role of epigenetics in development of chronic pain	53
Role of glial cells in chronic pain pathways	53

<i>Concluding remarks on evolution of acute pain into chronic pain</i>	53
Neurochemistry of pain.....	53
<i>Molecular elements of pain in the peripheral nervous system.....</i>	54
<i>Molecular elements of pain in the central nervous system</i>	55
<i>Opioid receptors</i>	56
<i>Role of AMPA receptors in chronic pain</i>	56
<i>Kinins.....</i>	56
<i>Serotonin.....</i>	57
<i>Substance P</i>	57
<i>Excitatory amino acids.....</i>	57
<i>Role of nitric oxide in pain.....</i>	58
<i>Prostaglandins.....</i>	58
<i>Endocannabinoids</i>	59
<i>Protein kinase C.....</i>	60
<i>Adenosine and adenosine receptors.....</i>	60
<i>Vitamin D and pain</i>	60
<i>Vanilloid receptor.....</i>	60
<i>TRPA₁ and TRPV₁ receptors.....</i>	61
<i>Endothelin-B receptors</i>	62
<i>Nerve growth factor and pain</i>	62
<i>Adrenomedullin as a pain-related peptide</i>	63
Biomarkers of pain.....	63
<i>Biomarkers of visceral pain</i>	63
2. Assessment of Pain and Analgesics	66
Introduction	66
Animal models of pain	66
<i>An overview</i>	66
<i>Selection of animal species as models for pain.....</i>	66
<i>Types of noxious stimuli</i>	67
<i>Animal models of neuropathic pain.....</i>	67
<i>Animal models of arthritis</i>	67
<i>Animal models of peripheral neuropathy</i>	68
<i>Limitations of current pain models</i>	68
<i>NeuroDigm GEL Model™ of neuropathic pain</i>	69
<i>Ethical issues concerning animal pain models</i>	69
Medical evaluation of pain	69
<i>Chronic pain as a manifestation of various diseases</i>	69
Assessment of pain patients	70
<i>Medical examination.....</i>	70
<i>Measurement of pain.....</i>	71
<i>Quality of pain intensity assessment in clinical research studies.....</i>	72
<i>Quantitative sensory testing.....</i>	73
<i>Pain measurement tools for neonates and children.....</i>	73
<i>Quantitative sensory testing.....</i>	74
<i>Microneurographic recordings.....</i>	74
<i>Psychological assessment of pain</i>	75
<i>Testing for in vivo pain processing</i>	75
<i>Brain imaging in pain</i>	75
<i>fMRI for study of pain.....</i>	75
<i>PET for study of pain</i>	75
<i>PET correlated with fMRI and evoked potentials</i>	76
<i>Patient outcomes and quality of life during treatment for chronic pain</i>	76
<i>Collection and analysis of data on pain patients</i>	77
Evaluation of analgesics in humans	77
<i>Early phase clinical trials of analgesics in humans</i>	77
<i>Design of clinical trials for pain</i>	78
<i>Assessment of neuropathic pain.....</i>	79
<i>Transdermal electrical stimulation for study of chronic pain</i>	79
<i>Placebo effect in pain</i>	80
<i>Role of electronic pain recording in determination of the placebo effect.....</i>	80
<i>Outcome measures for chronic pain trials.....</i>	80
<i>Pain, pain therapies and cognitive function.....</i>	81
3. Pharmacotherapy of Pain.....	82
Introduction	82
Sites of action of various pain therapies	82
Mechanism of action of currently used pain medications	83
Non-steroidal antiinflammatory drugs	84
<i>COX-2 inhibitors</i>	84
<i>Celecoxib</i>	85

<i>Metamizole</i>	86
<i>Nimesulide</i>	86
<i>Rofecoxib</i>	86
<i>Valdecoxib</i>	86
<i>Lumiracoxib</i>	87
<i>Side effects of COX inhibitors</i>	87
<i>Innovative COX-2 inhibitors in development</i>	89
<i>Acetaminophen</i>	89
Antioxidants as analgesics	90
Opiates and opioids	90
<i>Codeine</i>	91
<i>Morphine</i>	92
<i>Morphine vs methadone</i>	92
<i>Tramadol</i>	92
<i>Innovations in opioid therapy</i>	92
<i>Oral transmucosal fentanyl</i>	92
<i>Use of opioids for chronic non-cancer pain</i>	93
<i>Opioid receptor modulation for visceral pain</i>	93
<i>Opiorphin</i>	94
<i>Sufentanil</i>	94
N-methyl-D-aspartate receptor antagonists	94
<i>Ketamine</i>	94
<i>CNS 5161</i>	95
Triptans for treatment of non-migrainous pain	95
Capsaicin	95
<i>NGX-4010</i>	96
Local anesthetics	96
Topical application	96
Nerve blocks	96
<i>Injection of local anesthetics for analgesia</i>	97
<i>Ultrasound-guided nerve blocks</i>	97
Topical salicylates for the treatment of pain	97
Topical rubefacients for acute and chronic pain in adults	97
Adjunctive analgesics	98
Antidepressants	98
<i>Mechanism of analgesic action of antidepressants</i>	99
Antiepileptic drugs	100
<i>Mechanism of action of antiepileptic drugs in neuropathic pain</i>	101
<i>Carbamazepine</i>	101
<i>Gabapentin</i>	101
<i>Lamotrigine</i>	102
<i>Phenytoin</i>	102
<i>Pregabalin</i>	103
<i>Topiramate</i>	103
<i>Valproic acid</i>	104
<i>Other antiepileptic drugs</i>	104
<i>Clonidine</i>	104
<i>Baclofen</i>	105
<i>Corticosteroids</i>	105
<i>Calcitonin</i>	106
<i>Bisphosphonates</i>	106
<i>Botulinum toxins</i>	106
Analgesic effect of botulinum toxin A	107
Engineered botulinum toxin	107
Analgesics from traditional medical systems	107
Herbs and other plants	108
Analgesics derived from cobra toxin	108
4. Management of Pain	110
Introduction	110
Sites for pain management	110
Self-medication at home	110
Physicians' offices	110
Major hospitals	110
Pain centers	111
Non-pharmacological approaches to pain	111
Alternative medicine	111
<i>Acupuncture</i>	112
<i>Aromatherapy</i>	112
<i>Self-Controlled Energo Neuro Adaptive Regulation</i>	113
Behavioral therapy	113

<i>Cognition and pain</i>	113
<i>Control over brain activation and pain by using functional MRI.....</i>	113
<i>Mindfulness meditation for relief of chronic pain.....</i>	114
<i>Thermal-grill illusion.....</i>	114
<i>Virtual reality therapy.....</i>	114
Local application of heat	114
Transcutaneous nerve stimulation	115
Non-invasive brain stimulation techniques for chronic pain.....	115
<i>Transcranial magnetic stimulation</i>	115
<i>Cranial electrotherapy stimulation.....</i>	116
Neurosurgery for pain relief.....	116
<i>Ablative procedures on the nervous system.....</i>	116
<i>Procedures on peripheral, spinal and cranial nerves.....</i>	116
<i>Vagal nerve stimulation for control of pain</i>	117
<i>Neuromodulation</i>	117
<i>Spinal cord stimulation</i>	118
<i>Brain stimulation.....</i>	119
<i>Implantation of drug delivery devices</i>	120
Management of special types of pain	120
Acute pain	120
<i>Management of acute renal colic: NSAIDS vs. opioids.....</i>	120
<i>Combination of opioids and NSAIDs for acute pain</i>	120
<i>Reasons for inadequate management of acute pain</i>	121
Perioperative pain management.....	121
<i>Devices for delivery of analgesics in the postoperative period</i>	122
<i>Drug combination for perioperative pain</i>	123
<i>Gabapentin for reduction of postoperative pain</i>	123
<i>Ketamine for perioperative pain</i>	123
<i>Opioids for perioperative pain.....</i>	123
<i>Perioperative pain in neurosurgery</i>	124
<i>Prolonged duration local anesthesia.....</i>	125
<i>Concluding remarks on the management of postoperative pain.....</i>	125
Pain in the intensive care unit.....	125
Pain associated with sports and exercise.....	126
Pain associated with trauma.....	126
Chronic pain and sleep	127
Chronic abdominal pain	127
Functional somatic syndromes	127
Fibromyalgia syndrome.....	128
<i>Pathomechanism of FMS</i>	128
<i>Management of FMS.....</i>	129
<i>Non-pharmacological therapies for FMS</i>	129
<i>Pharmacotherapy of FMS</i>	129
<i>Concluding remarks on management of FMS</i>	131
Erythromelalgia	131
Irritable bowel syndrome	132
<i>Opioids for IBS</i>	132
<i>Pregabalin for IBS.....</i>	133
<i>Tricyclic antidepressants for IBS</i>	133
<i>Serotonin-modulating drugs for IBS</i>	133
Musculoskeletal pain	133
Myofascial pain syndrome	134
<i>Non-pharmacological methods of treatment of MPS.....</i>	134
<i>Pharmacotherapy of MPS</i>	134
Osteoarthritis	135
<i>Pain aggravates osteoarthritis by crosstalk between CNS and the joint</i>	136
<i>Management of osteoarthritis</i>	137
Rheumatoid arthritis.....	138
<i>Management of pain in rheumatoid arthritis</i>	138
<i>Disease modifying therapies in rheumatoid arthritis</i>	138
<i>Resurgence of interest in gold-based treatments for RA.....</i>	140
Backache and sciatica.....	140
<i>Lumbar disc disease and sciatica.....</i>	141
<i>Clinical trials of backache with sciatica</i>	142
<i>Management of back pain with analgesics</i>	142
<i>Miscellaneous medical therapies for backache and sciatica</i>	143
Neck pain.....	143
Chronic pelvic pain.....	144
<i>Prostatitis</i>	144
Cancer pain.....	145
<i>Adjuvant drugs for cancer pain</i>	145

<i>Alternative non-pharmacological methods</i>	146
<i>Anesthetic techniques</i>	146
<i>Management of bone pain in cancer</i>	146
<i>Non-opioid analgesics for cancer pain</i>	146
<i>Opioid treatment of cancer pain</i>	146
<i>Opioid breakthrough pains</i>	148
<i>Opioid-induced enhancement of cancer growth and its prevention</i>	148
<i>Opioids delivery methods for cancer pain</i>	148
<i>Opioid administration through implanted drug delivery devices</i>	149
<i>Radiation therapy</i>	150
<i>Surgical methods of cancer pain relief</i>	150
<i>Conclusions regarding management of cancer pain</i>	150
Chronic non-malignant pain	151
Headache	151
<i>Cluster headache</i>	152
<i>Chronic daily headache</i>	152
<i>Indomethacin-responsive headache</i>	153
<i>Occipital neuralgia</i>	153
<i>Paroxysmal hemicrania</i>	154
<i>Post-traumatic headache</i>	154
<i>Tension headache</i>	154
Migraine	155
<i>Management of acute migraine</i>	155
<i>Chronic migraine</i>	159
<i>Pediatric migraine</i>	160
<i>Status migrainosus</i>	161
<i>Migraine prophylaxis</i>	162
<i>Non-pharmacological approaches to migraine</i>	162
Trigeminal neuralgia	164
Dental pain	165
Neuropathic pain	165
<i>Pathogenesis of neuropathic pain</i>	165
<i>Chronobiology of neuropathic pain as guide to therapy</i>	166
<i>Management of neuropathic pain based on mechanism</i>	166
<i>Guidelines for the management of neuropathic pain</i>	167
<i>Pharmacotherapy of neuropathic pain</i>	167
<i>Evidence-based management of neuropathic pain</i>	169
Management of central neuropathic pain	170
<i>Neurosurgical approaches to central neuropathic pain</i>	170
<i>Management of neuropathic pain in syringomyelia</i>	171
<i>Neuropathic pain associated with spinal cord injury</i>	171
Management of peripheral neuropathic pain	171
<i>Truncal neuropathic pain</i>	172
<i>Management of postsurgical peripheral neuropathic pain</i>	172
<i>Management of chemotherapy-induced pain</i>	172
<i>Morton's neuroma</i>	173
<i>Management of peripheral diabetic neuropathy</i>	173
<i>Postherpetic neuralgia</i>	175
<i>Treatment of complex regional pain syndrome</i>	177
<i>An algorithm for the management of peripheral neuropathic pain</i>	178
Phantom limb pain	178
<i>Pathomechanism of phantom limb pain</i>	179
<i>Management of phantom limb pain</i>	179
Painful neuromas following amputation	181
Pain and depression	181
<i>Neurochemical link between pain and depression</i>	182
<i>Management of chronic pain and depression</i>	183
Miscellaneous painful conditions	183
<i>Burning mouth syndrome</i>	183
<i>Chronic unstable angina</i>	184
<i>Mastalgia</i>	184
<i>Ophthalmic pain</i>	184
<i>Pain in Parkinson's disease</i>	185
Pain in sickle cell disease	185
Management of chronic unexplained pain	186
Management of itching	186
<i>Topical applications for itching</i>	187
<i>Systemic therapies for itching</i>	188
<i>Non-pharmacological therapies for itch</i>	188
Management of pain in special population groups	188
Racial and ethnic differences in pain management	188

Pain in neonates	189
Management of pain in children	189
<i>Misuse of codeine in children</i>	191
Management of pain in the elderly	191
Management of pain in women	192
<i>Reasons for increased pain perception in women</i>	192
<i>Chronic pelvic pain in women</i>	193
<i>Gender differences in response to analgesics</i>	193
<i>Considerations for pain management in women</i>	193
Management of pain in neurologically handicapped persons	194
Management of pain in the cognitively impaired elderly people	194
Management of pain in brain-damaged minimally conscious patients.....	195
Management of pain in the terminally ill	195
Problems in the management of pain	195
Inadequate pain management	195
Problems with use of opioids	196
Excessive prescription of gabapentinoids.....	196
<i>Problems with use of gabapentinoids</i>	197
Patterns of analgesic consumption in France vs other European countries	197
Suggestions for improvement of pain management by healthcare providers	197
<i>Management of neuropathic pain refractory to first line treatment</i>	199
<i>Multidisciplinary approaches to pain management</i>	199
<i>Pain as the fifth vital sign</i>	200
<i>Reassessment of management of chronic pain</i>	200
<i>Guidelines for the management of acute pain</i>	200
5. Drug Delivery for Pain	202
Introduction	202
Intra-articular injection for relief of joint pain.....	203
Delivery of analgesics to peripheral nerves	203
Controlled release drug delivery for pain	204
Accelerating the effect of subcutaneous morphine	204
Controlled drug delivery at site of pain	204
Oral extended release opioids.....	205
<i>Extended release oral morphine</i>	205
<i>Controlled release oxycodone</i>	205
<i>Extended release oxymorphone</i>	205
<i>Oral extended release tramadol</i>	206
Extended release gabapentin.....	206
Use of nanotechnology for drug delivery for pain	206
Non-injection methods of delivery of analgesics.....	207
Topical applications for pain	208
<i>Topical local anesthetics</i>	208
<i>Topical NSAIDs</i>	208
<i>Topical and transdermal diclofenac</i>	209
<i>Topical application for postoperative pain</i>	209
Needle-free drug delivery for pain	209
<i>Glide SDI® solid dose injector</i>	210
<i>SUMAVENT™ DosePro™ needle-less injection</i>	210
Transdermal drug delivery for pain.....	210
<i>Relief of pain associated with minor medical procedures</i>	210
<i>Transdermal fentanyl</i>	211
<i>Transdermal ketoprofen</i>	212
<i>Transdermal nitroglycerine as an adjuvant to opioids</i>	212
<i>Transdermal buprenorphine</i>	212
<i>Transdermal trans-capsaicin</i>	213
<i>Powder Injection Systems</i>	213
Intranasal delivery of analgesics	214
<i>Intranasal morphine</i>	214
<i>Intranasal morphine derivatives</i>	214
<i>Intranasal fentanyl</i>	215
<i>Intranasal buprenorphine</i>	216
<i>Intranasal ketamine</i>	216
<i>Intranasal ketorolac</i>	216
<i>Nasal formulations for migraine</i>	216
Oral spray formulations for migraine	217
Delivery of analgesics by inhalation	217
Buccal transmucosal and sublingual delivery of analgesics	218
<i>Application for cancer pain</i>	218
<i>Application for non-cancer pain</i>	219
Pumps for drug delivery in pain	219

<i>Patient controlled analgesia</i>	219
<i>Postoperative pain pumps</i>	220
<i>Chronogenics (sufentanil) Pain Therapy System</i>	221
<i>PatchPump</i>	221
Intrathecal delivery of analgesics	222
Anatomical & physiological aspects of intrathecal drug delivery.....	222
Pharmacokinetics of intrathecal drug delivery	223
Epidural drugs	224
<i>Pharmacokinetics of analgesic drugs following epidural injection</i>	224
<i>Epidural glucocorticoids</i>	224
<i>Epidural etanercept</i>	224
<i>Epidural morphine</i>	225
Intrathecal drugs	225
<i>Intrathecal adenosine</i>	226
<i>Intrathecal baclofen</i>	227
<i>Intrathecal fadolmidine</i>	227
<i>Intrathecal lidocaine</i>	227
<i>Intrathecal magnesium sulfate</i>	227
<i>Intrathecal midazolam</i>	228
<i>Intrathecal opioids</i>	228
<i>Intrathecal neostigmine</i>	229
<i>Intrathecal octreotide</i>	229
<i>Intrathecal non-NMDA antagonists</i>	229
<i>Intrathecal prostaglandin antagonists</i>	229
<i>Intrathecal resiniferatoxin</i>	230
<i>Intrathecal ziconotide</i>	230
Combinations of intrathecal agents for relief of pain	231
Pumps for intrathecal delivery of analgesics	231
Complications of intrathecal delivery of analgesics	232
Concluding remarks on intrathecal delivery of analgesic agents	232
Intracerebroventricular morphine for pain	233
Development of drug delivery systems for pain therapy	233
Delivery of analgesics to the CNS across the blood brain barrier	233
Drug delivery systems in clinical trials	234
6. Drug Development for Pain.....	238
Introduction	238
Current research goals	238
An ideal analgesic	238
Challenges and prospects of pain therapeutic development	239
Priorities in pain research strategy in the US	239
Pain R & D goals in the pharmaceutical industry	240
Non-pharmacological therapies for pain	240
Drugs in development for pain.....	240
Drug targets in the spinal cord	241
Drug targets in the brain	241
Molecular targets for analgesic drugs	242
Opioid peptide receptors ligands	242
Opioid analgesics acting centrally	243
<i>Buprenorphine</i>	243
<i>Cebranopadol</i>	243
<i>Nociceptin</i>	243
<i>Opioids with unique receptor characteristics</i>	244
<i>Tapentadol</i>	244
Opioid analgesics acting outside the CNS	244
<i>Oliceridine</i>	244
<i>Opioid analgesics acting at peripheral receptors</i>	245
<i>Peripherally acting mu-opioid receptor agonists</i>	245
<i>Targeting of opioid peptide-containing immune cells</i>	246
<i>Advantages of peripherally selective opioid drugs</i>	246
Targets for non-opioid analgesics in development	246
Activation of P2X7 receptors.....	247
Alfa2-adrenergic receptor agonists	248
Angiotensin II type 2 receptor	248
Anti-NGF strategies	248
<i>Role of NGF in pain</i>	248
<i>Biological approaches to targeting the NGF pathway</i>	249
Bradykinin antagonists	249
Cannabinoids.....	250
<i>Cannabinoid receptor agonists</i>	250
<i>Cannabidiol</i>	252

<i>Cannabinor</i>	253
<i>Nabilone</i>	253
Capsaicin and VR1 receptor-based analgesics	254
<i>Vanilloid (capsaicin) receptor antagonists</i>	254
<i>VR1 receptor agonists</i>	254
CCR2 receptor blockade	254
Cholecystokinin antagonists	255
Cholinergic receptor agonists	255
Conotoxins as analgesics	256
Corticotropin-releasing factor	257
FAAH inhibitors	257
<i>PF-3845</i>	257
<i>URB597</i>	258
FKBP51 as a target for treatment of chronic pain	258
Free radical scavengers as analgesics	258
<i>Superoxide dismutase mimetics</i>	259
GABA analogs	259
<i>Subtype-selective GABAergic drugs</i>	259
Glutamate receptor antagonists	259
<i>NMDA receptor modulation for neuropathic pain</i>	260
<i>Alternatives to direct blocking of NMDA receptors</i>	260
<i>Glycine antagonists</i>	260
<i>Metabotropic glutamate receptors</i>	261
Histogranin-like compounds for the management of pain	261
Ion channels as targets for analgesic drugs	262
<i>Acid-sensing ion channels as drug target</i>	262
<i>Calcium channel blockers</i>	262
<i>HCN1 channels as targets for propofol analogs for neuropathic pain</i>	263
<i>P2X ion channel receptor antagonists</i>	263
<i>Sodium channel modulation</i>	264
Mas-related GPCR agonists	265
Microsomal prostaglandin E synthase inhibitors	265
NAALADase inhibitors	266
Neuropeptide receptor antagonists for improving the efficacy of opioids	266
Neurotrophic factor-based pain therapeutics	266
<i>Glial cell line-derived neurotrophic factor</i>	266
<i>Nerve growth factor antagonists</i>	267
Newer COX inhibitors	267
<i>COX-3 inhibitors</i>	267
<i>Dual cyclooxygenase/lipoxygenase inhibitors</i>	268
Nicotinic acetylcholine receptors	268
<i>Mode of action of nACh/neural nicotinic receptor agonists</i>	268
<i>Potential of central nACh/neural nicotinic receptor agonists</i>	269
Nitric oxide-based analgesics	269
<i>Nitric oxide-releasing NSAIDs</i>	270
<i>Pharmacology of NO-SAIDs</i>	270
<i>COX-inhibiting nitric oxide donors</i>	271
<i>NO-donating structures to extend life cycle of existing analgesics</i>	271
<i>Nitric oxide mimetics</i>	271
<i>Neuronal nitric oxide synthase inhibitors</i>	271
Norepinephrine transporter inhibition	272
Resolvins	272
Somatostatin analogs	272
Substance P and neurokinin receptor antagonists	273
Substance P-Saporin	273
Targeting prostanoid synthesis	274
Tetrodotoxin based analgesics	274
TRPV1 modulators	275
<i>TRPV1 antagonists</i>	275
<i>TRPV1 agonists</i>	276
<i>TRPV1-mediated entry of sodium channel blocker QX-314</i>	277
<i>TRPV1 receptors regulate longevity</i>	277
Tumor necrosis factor- α antagonists	277
Biological therapies for pain	278
Cell therapy for pain	278
Cells for delivery of antinociceptive molecules	279
Cell therapy for low back pain	279
Cell therapy for knee pain due to degenerative disorders	280
Cell therapy for peripheral neuropathic pain	280
Cell transplantation for relief of pain	280
<i>Transplantation of chromaffin cells</i>	280

<i>Transplantation of stem cells</i>	281
<i>Transplantation of astrocytes secreting enkephalin</i>	281
<i>Transplantation of cells for relief of neuropathic pain</i>	282
Concluding remarks on cell therapy for pain	282
Gene therapy for pain	283
Rationale of gene therapy for pain	283
<i>Gene therapy of peripheral neuropathy</i>	283
<i>Gene therapy targeted to neuroimmune component of chronic pain</i>	284
Methods of gene delivery for pain	284
Viral vector-mediated gene therapy of pain	285
<i>Vectors for endogenous analgesic production in cranial neuralgias</i>	285
Methods of gene delivery for pain	286
<i>Gene delivery by intrathecal route</i>	286
<i>Gene transfer to the dorsal nerve roots</i>	286
<i>Gene transfer by injections into the brain substance</i>	287
Antisense therapy for pain	287
RNAi-based approaches for pain therapy	288
Potential applications of gene therapy for management of pain	289
<i>Gene therapy for producing enkephalin to block pain signals</i>	289
<i>Gene therapy for upregulation of BMP in backache</i>	291
<i>Gene therapy for targeting nuclear factor-κB</i>	291
<i>Gene therapy for neuropathic pain</i>	291
<i>Zinc finger DNA-binding protein therapeutic for chronic pain</i>	292
Concluding remarks about gene therapy for pain	292
Preclinical development of pain drugs	293
NGF-blocking antibody	293
Prostatic acid phosphatase as a novel analgesic	294
Preclinical development of drugs for neuropathic pain	294
<i>5-HT receptor agonists</i>	295
<i>A-803467</i>	295
<i>a9a10 antagonists</i>	295
<i>AM1241</i>	296
<i>Artemin/Neuroblastin</i>	296
<i>Capsazepine</i>	297
<i>Central nACh receptor agonists</i>	297
<i>CGP 35024</i>	297
<i>Cortistatin</i>	298
<i>Drugs that suppress glial activation</i>	298
<i>Erythropoietin</i>	299
<i>NO donating GABA-agonist drugs</i>	299
<i>Resiniferatoxin</i>	299
<i>Targeting tumor necrosis factor</i>	300
Future targets for osteoarthritic pain	300
Pain drugs in clinical trials	300
Clinical trials of miscellaneous drugs for pain	300
<i>Alvimopan</i>	302
<i>Asimadoline</i>	303
<i>EN3202</i>	303
<i>Oxytrex</i>	303
Drugs in clinical trials for postsurgical pain	304
<i>Bicifadine</i>	304
<i>DepoMorphine</i>	305
Cox-2 inhibitors in clinical trials	306
Clinical trials of disease modifying therapies for arthritis	306
Drugs in clinical development for neuropathic pain	308
<i>Adenosine A1 agonists for neuropathic pain</i>	310
<i>Ajulemic acid</i>	310
<i>AVP-923 (dextromethorphan + quinidine)</i>	311
<i>Botulinum toxin type A</i>	311
<i>Carisbamate</i>	312
<i>CNV1014802</i>	312
<i>D-amino acid oxidase inhibitors</i>	312
<i>Glyx-13</i>	312
<i>IP-751</i>	312
<i>Lacosamide</i>	313
<i>Oxcarbazepine</i>	313
<i>Perampanel</i>	313
<i>Ralfinamide</i>	313
<i>Retigabine</i>	314
<i>SB-509</i>	314
<i>TC-6499</i>	314

<i>Tebanicline</i>	314
<i>Tezampanel</i>	315
<i>Thalidomide</i>	315
<i>TRO19622</i>	315
<i>V3381 (indantadol)</i>	316
<i>XP-13512</i>	316
<i>Zonisamide</i>	316
Drug discovery and development for migraine	317
<i>Drugs in clinical development for treatment of migraine</i>	317
<i>Clinical development of preventive therapies for migraine</i>	321
<i>Monoclonal antibodies targeting CGRP for migraine prophylaxis</i>	321
Drug development for visceral pain	322
7. Safety, Regulatory and Legal issues of pain management	324
Safety issues of analgesics	324
Adverse effects of analgesics.....	324
Cardiovascular adverse effects of COX-2 inhibitors.....	324
Gastrointestinal adverse effects of NSAIDs.....	324
<i>Measures to reduce gastrointestinal adverse effects of NSAIDs</i>	324
Adverse effects of opioids.....	325
Addiction and development of tolerance.....	325
<i>Alternatives to opioids</i>	325
<i>Buprenorphine as substitute for morphine addiction</i>	326
<i>Chronic pain and opioid addiction</i>	326
Abuse-deterrant opioid products	327
<i>Problems and limitations of abuse-deterrant opioids</i>	329
Complications of opioid abuse in the elderly	330
<i>Hyperalgesia associated with opioids</i>	330
<i>Narcotic bowel syndrome</i>	330
<i>Opioid use disorder</i>	331
<i>Opioid withdrawal</i>	331
<i>Opioid-associated constipation</i>	332
<i>Respiratory depression</i>	332
Guideline for use of opioids	332
Opioid regulations	333
Role of opioid prescribing patterns of physicians	334
Use of opioids for chronic noncancer pain.....	334
<i>Adverse effects of use of opioids in noncancer pain</i>	334
<i>Pharmacogenetics of adverse effects of codeine</i>	335
<i>PEGylated naloxol</i>	335
<i>Innovative approaches to modify opioid pharmacology</i>	336
Adverse effects of miscellaneous non-narcotic analgesics.....	336
<i>Adverse effects of immunosuppressants used for relief of pain</i>	336
<i>Adverse effects of acetaminophen</i>	336
<i>Hyponatremia as an adverse effect of tramadol</i>	336
Regulatory issues	337
Opioids	337
DEA and use of opioids for pain relief in terminal care	337
Cannabinoids.....	337
FDA and COX-2 inhibitors.....	338
Legal issues of COX-2 inhibitors	338
Regulatory aspects of opioid safety and abuse	339
Opioid misuse and regulatory agencies	339
FDA measures for safety of opioid use	339
Misuse of fentanyl.....	341
Regulation of extended release and long-acting opioids	341
Pain relief as a legal right	342
Pain relief and the WHO.....	342
8. Pain Markets.....	344
Introduction	344
Epidemiological basis of pain markets	344
Cancer.....	345
Neuropathic pain.....	345
Trigeminal neuralgia.....	345
Arthritis	345
Backache	345
Migraine	346
Multiple sclerosis.....	346
Irritable bowel syndrome	346
Chronic pelvic pain.....	346

Chronic pain due to traumatic brain injury	346
Postsurgical pain.....	347
Economics of pain.....	347
Pain as a driver of healthcare costs	347
Disability and financial loss through pain in the US.....	348
Targeted delivery of analgesics for cancer pain	348
Pain markets based on painful conditions.....	348
The cancer pain market	349
The arthritis pain market	349
Postsurgical pain market.....	350
The backache market	350
The headache market.....	350
Neuropathic pain market.....	350
Fibromyalgia market	351
Pain markets based on drugs.....	351
Opioids.....	352
Nonsteroidal antiinflammatory drugs	352
Transdermal pain therapeutics.....	353
Anesthesia	353
Antiepileptic drugs as analgesics	353
Other drugs.....	353
Hospital vs retail share of pain market.....	353
<i>Hospital versus retail opioid market.</i>	354
Devices for pain.....	354
Pain markets according to geographical areas.....	354
Cost effectiveness of various approaches	355
Unfulfilled R&D needs in pain therapy	355
Under treatment of pain	355
Unfulfilled needs in drug development for chronic pain	355
Strategies for developing pain markets	356
Finding alternatives to intrathecal administration for chronic pain	357
Development of other applications of analgesic drugs.....	357
Partnership of patients, pharmacists and companies.....	357
Factors that may influence future pain markets	358
Drivers of pain markets	358
Public surveys as indicators of impact of pain on people.....	358
Effect of regulatory reviews on markets for pain products	359
Novel versus older therapies for pain.....	359
9. Future of Pain Therapeutics	360
Introduction	360
Advances in the understanding of pain	360
Pathogenesis of chronic pain	360
Role of glia in neuropathic pain.....	360
Molecular and neurobiological techniques.....	361
Improved understanding of cancer pain	362
Advances in drug discovery and development for pain	362
Novel targets for drug discovery for pain	362
<i>PTH2 receptor .</i>	362
<i>Modulators of endogenous cannabinoids</i>	363
Application of new technologies to pain therapeutics	363
<i>Application of nanobiotechnology to pain therapeutics</i>	364
<i>Technologies for the manufacture of analgesics</i>	365
Future trends and needs in pain management	365
Pain management in future healthcare systems	366
Systems biology approach to pain	366
Personalized management of pain	367
Genetic factors in response to pain.....	368
Genetic mutations with loss of pain	369
Genetic mutations and painful conditions	369
Mechanism-specific management of pain	369
Gene expression biomarkers for personalizing pain management	370
Pharmacogenomics and pharmacogenetics of pain	370
Personalized management of pain with commonly used analgesics.....	371
<i>Personalized opioid therapy for noncancer pain.</i>	371
<i>Pharmacogenomics and pharmacogenetics of opioids</i>	371
<i>Pharmacogenetics of COMT gene and pain</i>	372
<i>Pharmacogenetics of NSAIDs and pain.</i>	373
Preoperative testing to tailor postoperative analgesic requirements.....	373
Prediction of response to an analgesic by in vitro iPSC based testing	373
Role of conditioned pain modulation in personalized management of pain	374

Signature of pain on brain imaging.....	374
Future of personalized pain management.....	374
Strategies for improving pain management.....	374
Research on pain in Europe	375
Concluding remarks on future of pain management	376
10. Companies Involved in Pain Therapeutics.....	378
Introduction	378
Profiles of companies.....	378
Collaborations.....	559
11. References.....	564

Tables

Table 1-1: Landmarks in the history of pain therapeutics	21
Table 1-2: Classification of pain.....	23
Table 1-3: Classification of neuropathic pain	25
Table 1-4: Classification of chronic cancer pain according to cause.....	27
Table 1-5: Percentage of patients with pain according to the type of cancer	28
Table 1-6: TRP channels involved in the regulation of pain and itch.....	47
Table 1-7: Key molecular elements of pain in the peripheral nervous system	55
Table 1-8: Key molecular elements of pain in the central nervous system.....	55
Table 2-1: IASP guidelines for the use of animals in pain studies	69
Table 2-2: Chronic pain as a manifestation of other diseases.....	70
Table 2-3: Recommendations for assessing patient satisfaction with pain management.....	76
Table 3-1: Classification of some currently used pain medications according to mechanism.....	83
Table 3-2: Drugs used for the treatment of pain	83
Table 3-3: Selective COX-2 inhibitors in clinical use for pain.....	85
Table 3-4: Antiepileptic drugs with analgesic effect	100
Table 4-1: Non-pharmacological approaches to management of pain	111
Table 4-2: Companies involved in neuromodulation therapy for pain	117
Table 4-3: Reasons for the inadequate management of acute pain.....	121
Table 4-4: Monoclonal antibodies as disease modifying therapies in rheumatoid arthritis	139
Table 4-5: Causes of chronic backache	140
Table 4-6: Management of chronic pelvic pain	144
Table 4-7: Management of pain in cancer	145
Table 4-8: Definitions of tolerance, physiological dependence, withdrawal and addiction.....	151
Table 4-9: A simplified classification of headache.....	151
Table 4-10: Various methods for the management of acute migraine	155
Table 4-11: Prophylaxis and management of chronic migraine	159
Table 4-12: Evidence-based level of choice of drugs for prophylaxis of migraine	162
Table 4-13: Management of neuropathic pain based on mechanism and diagnosis	166
Table 4-14: Management of central neuropathic pain	170
Table 4-15: Current management of peripheral diabetic neuropathy	173
Table 4-16: Treatment strategies for postherpetic neuralgia.....	175
Table 4-17: Management of complex regional pain syndrome.....	177
Table 4-18: Methods of treating phantom limb pain	179
Table 4-19: Treatment of chronic unexplained pain due to central sensitization	186
Table 4-20: Anti-itching therapies.....	186
Table 4-21: Suggested improvements in the management of pain	198
Table 5-1: A classification of drug delivery methods used in management of pain	202
Table 5-2: Selected marketed non-injection drug delivery systems for pain	207
Table 5-3: Approved drugs for spinal administration for pain.....	225
Table 5-4: Off-label intrathecal use of drugs for pain	225
Table 5-5: Experimental studies of intrathecal administration of drugs for analgesia	226
Table 5-6: Intrathecal drugs for pain in clinical trials	226
Table 5-7: Comparison of pharmacokinetics of lipophilic with hydrophilic opioids	228
Table 5-8: Delivery systems for pain (other than intrathecal) in clinical development	235
Table 6-1: Classification of drugs in development for pain	240
Table 6-2: Major opioids receptors and their ligands	242
Table 6-3: Therapeutic targets for non-opioid analgesic drugs in development	246
Table 6-4: Preclinical studies on cannabinoid (CB ₂) receptor agonists as analgesics	251
Table 6-5: Cannabinoid receptor agonists in clinical development as analgesics.....	252
Table 6-6: NO-related therapies for pain.....	269
Table 6-7: Strategies to counteract pain at various levels at periphery and in the CNS	274
Table 6-8: Types of TRPV1 antagonists	276
Table 6-9: TRPV1 antagonists in clinical trials.....	276
Table 6-10: Biological therapies for pain	278

Table 6-11: Experimental gene therapy approaches for relief of pain.....	284
Table 6-12: Selected preclinical approaches to pain therapy.....	293
Table 6-13: Selected preclinical drugs for neuropathic pain.....	294
Table 6-14: Selected clinical trials of miscellaneous drugs for pain	301
Table 6-15: Selected clinical trials of drugs for postsurgical pain.....	304
Table 6-16: COX-2 inhibitors in clinical development.....	306
Table 6-17: Disease modifying drugs for arthritis in clinical trials	306
Table 6-18: Clinical trials of drugs for neuropathic pain	308
Table 6-19: Selected drugs in clinical development for migraine	317
Table 6-20: CGRP receptor antagonists in clinical development for acute migraine.....	319
Table 6-21: Clinical trials of anti-CGRP monoclonal antibodies for migraine prevention	322
Table 6-22: Therapeutic targets for treating visceral pain	322
Table 7-1: Abuse-deterrant opioid products	328
Table 7-2: Diagnostic criteria for an opioid-use disorder	331
Table 8-1: Market values for various painful conditions 2020-2030	349
Table 8-2: Changes in market shares of drugs for neuropathic pain 2020-2030	351
Table 8-3: Markets for pain according to therapies 2020-2030	352
Table 8-4: Distribution of value of pain therapeutics in major markets 2020-2030	354
Table 8-5: Distribution of value of opioids in major pain markets 2020-2030.....	354
Table 8-6: Distribution of value of NSAIDs in major pain markets 2020-2030.....	355
Table 8-7: Strategies for developing pain markets	356
Table 9-1: P450 isoforms in the metabolism of drugs used in the management of pain.....	370
Table 10-1: Top companies in pain therapeutics	378
Table 10-2: Product pipeline of Adolor Corporation	385
Table 10-3: Selected collaborations in the area of pain management	559

Figures

Figure 1-1: Afferent pain pathways.....	30
Figure 1-2: Pain organ of the skin.....	31
Figure 1-3: Evolution of the gate control theory.....	33
Figure 1-4: The body self-neurometric.....	33
Figure 1-5: Various ligands and receptors on the peripheral terminals of nociceptive nerve fibers	55
Figure 1-6: Prostaglandin biosynthesis pathway	59
Figure 2-1: Biopsychosocial factors that interact and modulate the experience of pain.....	71
Figure 2-2: Pain intensity scales	72
Figure 3-1: Sites of action of various methods of pain management.....	82
Figure 3-2: Pathway of metabolism of codein	91
Figure 4-1: The WHO step ladder for pain	147
Figure 4-2: An algorithm for the acute management of migraine	157
Figure 4-3: Neuroimmune activation events leading to sensitization of CNS	165
Figure 4-4: An algorithm for the management of peripheral neuropathic pain.....	178
Figure 4-5: Algorithm for management of patients with chronic pain and depression	183
Figure 5-1: Powder Injection Systems	213
Figure 5-2: Penetration of CSF into spinal cord	222
Figure 5-3: Disposition of opioids after intrathecal administration	224
Figure 6-1: Attributes of the ideal analgesic	238
Figure 6-2: Role of NGF in pain.....	249
Figure 6-3: Nerve targeting drug delivery system for gene therapy of pain	290
Figure 8-1: Unfulfilled needs in the treatment for chronic pain.....	356
Figure 9-1: Impact of new technologies on pain therapeutics	364
Figure 9-2: Essential components of personalized management of pain	367
Figure 9-3: Personalized opioid therapy for noncancer pain.....	371
Figure 9-4: Genetic and non-genetic factors affecting efficacy and side effects of opioids.....	372